OC - Drospirenone plus Ethynylestradiol — Competitive Intelligence Brief

OC - Drospirenone plus Ethynylestradiol (OC - Drospirenone plus Ethynylestradiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Gynecology.

marketed Combined oral contraceptive Estrogen receptor, progesterone receptor, mineralocorticoid receptor Contraception / Gynecology Small molecule

Target snapshot

OC - Drospirenone plus Ethynylestradiol (OC - Drospirenone plus Ethynylestradiol) — Federico II University. Drospirenone and ethinylestradiol work together as an oral contraceptive by suppressing ovulation through progestin and estrogen activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OC - Drospirenone plus Ethynylestradiol TARGET	OC - Drospirenone plus Ethynylestradiol	Federico II University	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor, mineralocorticoid receptor
EE20/DRSP (YAZ, BAY86-5300)	EE20/DRSP (YAZ, BAY86-5300)	Bayer	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor, progesterone receptor, mineralocorticoid receptor
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
desogestrel/ethinyl estradiol	desogestrel/ethinyl estradiol	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Estradiol+Drospirenone	Estradiol+Drospirenone	Brigham and Women's Hospital	marketed	Combined oral contraceptive	Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism
Ethinyl estradiol / dienogest	Ethinyl estradiol / dienogest	Helsinki University Central Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
OCR	OCR	Hoffmann-La Roche	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class